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Abstract
Lentiviral Nef proteins have multiple functions and are important for viral pathogenesis. Recently, Nef proteins from many
simian immunodefiency viruses were shown to antagonize a cellular antiviral protein, named Tetherin, that blocks release of
viral particles from the cell surface. However, the mechanism by which Nef antagonizes Tetherin is unknown. Here, using
related Nef proteins that differ in their ability to antagonize Tetherin, we identify three amino-acids in the C-terminal
domain of Nef that are critical specifically for its ability to antagonize Tetherin. Additionally, divergent Nef proteins bind to
the AP-2 clathrin adaptor complex, and we show that residues important for this interaction are required for Tetherin
antagonism, downregulation of Tetherin from the cell surface and removal of Tetherin from sites of particle assembly.
Accordingly, depletion of AP-2 using RNA interference impairs the ability of Nef to antagonize Tetherin, demonstrating that
AP-2 recruitment is required for Nef proteins to counteract this antiviral protein.
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Introduction
Human and simian immunodeficiency viruses encode several
small, so called ‘accessory’, proteins that do not appear to be
required for viral replication in most in vitro replication systems.
Nevertheless, it has become apparent that several of these accessory
proteins play important roles in antagonizing host proteins, known
as restriction factors, that inhibit viral replication. Specifically, Vif
antagonizes members of the APOBEC3 family of cytidine
deaminases whereas Vpu and Nef antagonize Tetherin (reviewed
in [1]). There is also emerging evidence suggesting that Vpx might
also antagonize yet unidentified host restriction factors [2–4].
Tetherin (BST-2/CD317/HM1.24) is a cell surface membrane
protein with an unusual topology, consisting of a short N-terminal
cytoplasmic tail (CT), a transmembrane domain (TM), an
extracellular coiled-coil and a glycophosphatidyl inositol anchor at
the C-terminus [5–8]. This topology, rather than primary sequence
appears key for Tetherin’s ability to retain nascent mature viral
particles at the cell membrane [9]. Indeed, an artificial Tetherin
assembled from domains of heterologous proteins with no sequence
homology to natural Tetherins is active [9]. Tetherin appears to
work by inserting either of its membrane anchors into the lipid
envelope of nascent virions. In so doing, it physically bridges the
nascent virion and cellular plasma membranes thereby preventing
virions from disseminating to infect other target cells [10,11]. Thus,
the spectrum of activity of Tetherin proteins against enveloped
viruses is broad and includes retroviruses, filoviruses, arenaviruses,
rhabdoviruses and herpes viruses [12–17].
Perhaps because Tetherin targets the lipid envelope, an almost
invariant component of the virion, to block particle release,
divergent viruses evolved various strategies and proteins to
counteract Tetherin. HIV-1 uses Vpu, a type-I transmembrane
protein [10,11], Ebola uses its envelope protein [13] and Kaposi’s
sarcoma-associated herpesvirus uses the viral RING-CH E3
ubiquitin ligase K5 [14,15]. Interestingly, even among relatively
closely related primate lentiviruses, three different viral proteins
(Vpu, Nef and Env) have assumed the function of Tetherin
antagonism [10,11,18–21]. Vpu is encoded by a subset of primate
lentiviruses including HIV-1, its direct chimpanzee-derived
ancestor (SIVcpz) and the SIVgsn/mus/mon lineage whose 39
portion of the genome, including Vpu, shares a common origin
with SIVcpz/HIV-1 [22]. Vpu proteins from HIV-1 and SIVgsn/
mus/mon antagonize Tetherin proteins from their respective hosts
[20,23,24]. Even though both its direct descendent (HIV-1) and its
ancestors (the SIVgsn/mus/mon lineage) use Vpu to antagonise
Tetherin, SIVcpz instead employs Nef for this function. In fact
with the exception of HIV-2 [19], that uses the envelope
glycoprotein, all other primate that lack Vpu and have been
tested encode Nef proteins that can counteract Tetherin
[18,20,21,24].
The diverse nature of Tetherin antagonists that have arisen in
primate lentiviruses is a consequence of the diversity in Tetherin
sequence among primates, particularly at the target sites for Vpu
and Nef, that the ancestors of modern viruses encountered as they
were transmitted from species to species. Tetherin sequence
diversity also means that the antagonists often exhibit species-
specific activity. For example, SIVMAC Nef antagonizes macaque
(mac) Tetherin but is less active against African Green monkey
(agm) Tetherin and inactive against human (hu) Tetherin, whereas
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is not active against huTetherin [21]. A key determinant of
sensitivity to Nef proteins is a five amino acid motif in the Tetherin
CT [18,21]; huTetherin is unique amongst primate Tetherins in
that it lacks these five amino acids, and is resistant to all Nef
proteins studied to date [20].
Nef is a 27–35 kD protein that is composed of (i) an N-terminal
myristoyl membrane anchor, (ii) a flexible polypeptide chain that
varies in length among Nef proteins, (iii) a polyproline helix type II
that mediates interaction with SH3 domains (iv) a core domain
that assumes a globular structure and is generally conserved
among Nef proteins (iv) a C-terminal domain of unknown
structure (reviewed in [25]). Nef proteins have been shown to
downregulate several cell surface molecules, exploiting distinct
cellular protein partners that interact with distinct Nef sequences
for downregulation of various targets ([26,27], reviewed in [28]).
Thus, Nef recruits AP-1 to target MHC-I from the trans-Golgi to
the lysosomes [29,30] and induces MHC-I endocytosis from the
plasma membrane [31]. Conversely, Nef promotes endocytosis of
CD4 from the cell surface and a critical dileucine motif in Nef was
shown to be required for both this activity and Nef binding to AP
complexes [32,33,34,35]. It was subsequently demonstrated that
HIV-1 Nef employs two distinct motifs to form a complex with
AP-2: an EXXXLL motif interacts with the AP-2 a-s2
hemicomplex and a DD motif mediates additional interactions
with AP-2 a and thus recruits AP-2 to mediate CD4 downreg-
ulation [36,37]. Notably, both AP-2 interaction motifs are
conserved in Nef proteins from a variety of SIVs.
The protein domains, cellular partners and mechanisms
employed by Nef proteins to counteract Tetherin are unknown.
Here we identify three key amino acid residues within SIVcpz Nef
C-terminal flexible loop that are specifically required for Tetherin
antagonism. We also demonstrate that Tetherin antagonism by
Nef proteins from divergent SIVs is accompanied by the removal
of Tetherin from sites of particle assembly and reduction of its
levels at the cell surface, without effects on overall expression
levels. We show that the two motifs in the Nef flexible C-terminal
region that mediate interaction with AP-2 are also critical for these
activities and, concordantly that AP-2 is required for Nef to
antagonize Tetherin.
Results
Nef determinants specifically required for Tetherin
antagonism
We and others have previously shown that five amino acids in
the Tetherin CT are necessary and sufficient to confer sensitivity
to antagonism by Nef [18,21]. To determine regions of Nef that
are specifically required for Tetherin antagonism, we selected two
Nef proteins that are closely related but differ in their ability to
antagonize Tetherin. Specifically, SIVcpzGb1 Nef is a potent
antagonist of cpzTetherin while HIV-1 Nef is completely inactive,
even though the two proteins share ,70% amino acid homology
(Figure 1A). We generated a series of chimeric SIVcpz/HIV-1 Nef
proteins, depicted in Figures 1A and 1B, and assayed their ability
to antagonize cpzTetherin when co-expressed, in trans, with an
HIV-1 construct lacking Vpu and Nef. Chimeric Nef protein
expression was confirmed using western blot analyses with an
antibody that recognizes both proteins (Figure 1C and 1D).
Replacing increasingly larger portions of the N-terminal portion of
the HIV-1 Nef protein by the corresponding regions from
SIVcpzGb1 Nef gave rise to chimeras HIV/Gb-1 through -5.
HIV/Gb-1,-2,-3 and -4, containing up to 147 N-terminal residues
from SIVcpzGb1 Nef had the same phenotype as HIV-1 Nef in
that they were unable to antagonize cpzTetherin. However,
inclusion of the N-terminal 181 residues from SIVcpzGb1 Nef
allowed the resulting HIV/Gb-5 chimera to antagonize
cpzTetherin as efficiently as wild-type SIVcpzGb1 Nef
(Figure 1C and Figure S1A). In a reciprocal set of chimeras,
HIV/Gb-6 to HIV/Gb-10, SIVcpzGb1 Nef N-terminal sequences
were replaced by those from HIV-1 Nef (Figure 1B). Chimeras
HIV/Gb-6, -7, -8 and -9 that contained up to 147 N-terminal
residues from HIV-1 Nef maintained cpzTetherin antagonism
activity. However, replacement of 181 N-terminal residues by
those from HIV-1 Nef, in the HIV/Gb-10 chimera, abolished its
activity (Figure 1C and Figure S1A). There was only slight
variation in the expression of these chimeric Nef proteins that did
not correlate with their ability to counteract cpzTetherin
(Figure 1C and 1D) and Nef expression levels were not affected
by Tetherin expression (Figure S1B).
These data suggested that amino acids 148 to 181 of SIVcpzGb1
Nef contained key determinants of Tetherin antagonism. Thus, as
expected, replacement of amino acids 148–181 in HIV-1 Nefby the
corresponding residues from SIVcpzGb1 Nef resulted in chimera
HIV/Gb-11 (Figures 1A and 1B) that was capable of antagonizing
cpzTetherin restriction slightly less efficiently than wild-type
SIVcpzGb1 Nef (Figure 1D and Figure S1C). The reciprocal
chimera HIV/Gb-12, that contained HIV-1 Nef residues 148–181,
in an otherwise SIVcpzGb1 background was unable to antagonize
cpzTetherin. Subsequently, smaller portions of HIV-1 Nef within
this region were substituted by the corresponding residues from
SIVcpzGb1 Nef, generating chimeras HIV/Gb-13, -14 and -15
(Figure 1A and 1B). Chimera HIV/Gb-15 was unable to counteract
cpzTetherin. In contrast both chimeras HIV/Gb-13 and -14 that
encoded SIVcpzGab1 Nef residues 148–158 and 159–167,
respectively, were able to antagonize cpzTetherin (Figure 1D and
FigureS1C).Comparedtowild-typeSIVcpzGb1 Nef,theactivityof
these chimeras was somewhat reduced (Figure 1D and Figure S1C),
suggesting that determinants withinboth regions 148–158 and 159–
167 contribute to cpzTetherin antagonism. These chimeras were all
expressed at comparable levels (Figure 1D and Figure S1D).
Importantly, all of the aforementioned Nef chimeras maintained
CD4 downregulation activity (Figure S1E), even though some
chimeras exchanged Nef regions that have been shown to be
required for CD4 downregulation [36,37]. This result demonstrates
that Nef functions other than Tetherin antagonism were not grossly
affected in the chimeras.
CpzTetherin antagonism is a conserved property of Nef
proteins from SIVcpz strains and absent from all the HIV-1 M-
group strains studied thus far [20]. In amino acid region 148–158
several amino acids differed between the HIV-1 and SIVcpz Nef
Author Summary
Primate lentiviruses express several small proteins which
antagonize cellular proteins that inhibit virus replication.
One such viral protein, Nef, has recently been shown to
antagonize the cellular protein Tetherin that prevents
newly formed viral particles from leaving the surface of
infected cells. In this study we reveal the mechanism by
which Nef overcomes inhibition by Tetherin. We show that
three amino acids in the Nef C-terminal flexible loop are
important for Tetherin antagonism. We also show that the
interaction between Nef and AP-2 adaptor complexes is
important for Tetherin downregulation from the cell
surface, removal from sites of particle assembly and
antagonism. Thus, our study demonstrates that AP-2 is
important for the ability of Nef to antagonize Tetherin.
Nef Antagonism of Tetherin Requires AP-2
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segregated according to whether the Nef proteins previously tested
were from HIV-1 group M or SIVcpz strains (Figure 1A and [20]).
In region 159–167, amino acids at positions 162 and 163 differed
between HIV-1 Nef and SIVcpzGb1 Nef (Figure 1A), although
their identity did not segregate perfectly between HIV-1 and
SIVcpz Nef proteins [20]. Based on this analysis, we generated
three mutant HIV-1 Nef proteins: 1) HIV-1Q, harboring one
amino acid change: K152Q, 2) HIV-1NC, harboring two amino
acid changes: T162N and S163C and 3) HIV-1QNC, where all
three substitutions K152Q, T162N and S163C were made. Both
the HIV-1Q and HIV-1NC mutants antagonized cpzTetherin,
albeit with reduced efficiency compared to SIVcpzGb1 Nef
(Figure 2 and Figure S2A). The combination of all three amino
acid changes, in HIV-1QNC did not increase the efficiency of
cpzTetherin antagonism over the HIV-1Q and HIV-1NC mutants
suggesting that other residues within amino acid stretches 148–167
also contribute to anti-Tetherin activity. Protein expression levels
were comparable for all mutant and wild type proteins (Figure 2
and Figure S2B).
In a reciprocal panel of SIVcpzGb1 mutants, introduction of
the single mutation Q152K in SIVcpzGb1 Nef (Gb1-K) did not
significantly affect its ability to inhibit cpzTetherin whereas a
double mutation N162T and C163S (Gb1-TS) resulted in a very
modest (2-fold) reduction in activity (Figure 2 and Figure S2A).
However, when all three amino acid changes were combined, in
Gb1-KTS, the resulting Nef protein was significantly impaired in
its ability to antagonize cpzTetherin. The Gb1-KTS Nef protein
retained its ability to downregulate CD4 although it was slightly
less efficient than the parental and the other mutant Nef proteins
(Figure S2C). These data indicate that residues Q152, N162 and
C163 specifically affect the ability of SIVcpzGb1 Nef to counteract
cpzTetherin, although other residues in the 148–167 domain also
contribute to this activity.
The AP-2 binding sites in SIVMAC, SIVagm and SIVcpz Nef
proteins are required for Tetherin antagonism
We have previously shown that a mutation in SIVMAC Nef
(D204R) that inhibits CD4 downregulation also reduces its ability
to counteract rhTetherin while a mutation that abolishes MHC-I
downregulation (Y223F) does not affect Tetherin antagonism [21].
Because MHC-I downregulation by Nef requires AP-1 [30] while
CD4 downregulation is mediated through AP-2 recruitment [36],
it seemed plausible that Nef might recruit AP-2 to remove
Tetherin from the cell surface and rescue virus release. Two motifs
in the HIV-1 Nef C-terminal flexible loop are required for
interaction with AP-2, namely EXXXLL165 and DD175 (Figure 1A)
[36,37]. SIVMAC Nef proteins bearing mutations at the corre-
sponding motifs (EEHYLM195 to AEHYAA and D204 to R) were
expressed as fusion proteins with the fluorescent protein Venus at
the C-terminus. The wild type SIVMACNef-Venus fusion protein
efficiently antagonized rhTetherin, but as we have previously
shown [21], the D204R mutation abolished this activity (Figure 3A
and Figure S3A). Similarly, mutation of the leucine-based motif
(EXXXLM195/AXXXAA) in SIVMAC Nef that mediates interac-
tion with the AP-2 a-s2 hemicomplex [36] also abolished
rhTetherin antagonism.
Figure 2. Identification of Nef amino acids important for
Tetherin antagonism. Quantitative fluorescence-based Western blot
analysis of particle release. HIV-1 lacking Vpu and Nef was expressed
together with the Nef proteins (in trans) indicated in the presence or
absence of cpzTetherin. Cell and virion lysates were probed with an
anti-capsid antibody. Cell lysates were also probed with anti-HA
monoclonal antibody and an anti-HIV-1 Nef antibody that also
recognizes SIVcpzGb1 Nef. The results shown are representative of at
least 3 independent experiments. (See also Figure S2.).
doi:10.1371/journal.ppat.1002039.g002
Figure 1. Mapping Tetherin antagonism determinants in Nef. (A) Amino acid alignment of HIV-1 (NL4.3) and SIVcpzGb1 Nef proteins.
Identical residues are boxed. Arrows indicate the junctions at which chimeras between the proteins were generated. Stars indicate amino acids that
were mutated in proteins used in Figure 2. (B) Schematic representation of chimeras generated between HIV-1 and SIVcpzGb1 Nef proteins. White
boxes represent HIV-1 Nef-derived sequences and black boxes represent SIVcpzGb1 Nef-derived sequences. The amino acid number at which the
junction between the two proteins was generated is indicated at the top of the diagram. (C and D) Quantitative fluorescence-based Western blot
analysis of particle release. HIV-1 lacking Vpu and Nef was expressed together with the Nef proteins (in trans) indicated in the presence or absence of
cpzTetherin. Cell and virion lysates were probed with an anti-capsid antibody. Cell lysates were also probed with anti-HA monoclonal antibody and
an anti-HIV-1 Nef antibody that also recognizes SIVcpzGb1 Nef. The results shown are representative of 2-3 independent experiments. (See also
Figure S1.).
doi:10.1371/journal.ppat.1002039.g001
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PLoS Pathogens | www.plospathogens.org 4 May 2011 | Volume 7 | Issue 5 | e1002039Figure 3. Mutation of Nef residues required for AP-2 binding abolish Tetherin antagonism. (A) Quantitative Western blot analysis of
particle release for SIVMAC based viruses lacking Nef, co-expressed with the indicated wild type or mutant SIVMAC Nef proteins fused to Venus (in
trans) in the presence or absence of rhTetherin. Cell and virion lysates were probed with an anti-HIV-1-capsid antibody. Cell lysates were also probed
with anti-HA and anti-GFP monoclonal antibodies to determine rhTetherin and Nef-Venus protein expression levels respectively. The results shown
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of SIVMAC Nef residues, previously reported to mediate interaction
with several cellular proteins, we tested Nef proteins that were
mutated at the following positions: 1) Y28 (to A) that has been
suggested to affect interactions with AP-1 and AP-2 proteins
[38,39], 2) W70 (to R) that corresponds to residue W57 in HIV-1 Nef
shown to beinvolved inCD4binding[40],3)D155(toG)that affects
Nef dimerization [41] and 4) R138R139 (to AA) that affects Pak1/2
binding[42].None ofthe abovemutationshadmajoreffects(,2–3-
fold) on particle release in experiments where SIVMACNef was
asked to antagonize rhTetherin (Figure 3A and Figure S3A). These
data suggest that mutations that impair SIVMAC Nef interactions
with other proteins do not generally affect its ability to antagonize
rhTetherin. The notable exceptions were mutations that disrupt the
leucine-based and diacidic motifs involved in AP-2 binding.
These two AP-2-binding motifs are highly conserved among
lentiviral Nef proteins and we therefore asked whether their
mutation in other Nef proteins from SIVagm and SIVcpzGb1 that
antagonize Tetherin, would also affect their activity. Indeed,
mutation of either AP-2-binding motif in SIVagmSab Nef,
EXXXLL183 or DD193, significantly reduced the ability of
SIVagmSab Nef to rescue particle release from inhibition by
agmTetherin (Figure 3B and Figure S3B). Similarly, mutation of
the DXXXLL165 motif in SIVcpzGb1 Nef completely abolished
its ability to counteract cpzTetherin (Figure 3C and Figure S3C).
AP-2 has been previously shown to interact with HIV-1 and
SIVMAC Nef [36,38], but not with SIVagmSab or SIVcpzGb1
Nef. We used a previously described yeast-3-hybrid assay to test
for such an interaction [36,37]. The Nef proteins were fused to the
Gal4 binding domain in a vector also expressing the AP-2 s2
subunit and tested for interaction with a vector expressing the AP-
2 a subunit and the VP16 activation domain. Like HIV-1 Nef,
SIVagmSab Nef interacted with AP-2 a-s2 hemicomplex, and
mutation of either the EXXXLL183 motif or DD193 abolished this
interaction (Figure 3D). Unfortunately, in our hands both SIVMAC
and SIVcpzGb1 Nef proteins induced activation of transcription
even in the absence of AP-2 subunits and thus could not be tested
in this assay. Therefore, we used an alternative assay to determine
whether the Nef-Venus fusion proteins co-localized with endog-
enous AP-2 in mammalian cells. Indeed all three proteins
SIVMAC, SIVagmSab and SIVcpzGb1 Nef showed a clear and
obvious co-localization with AP-2 at the cell surface (Figure S4).
Altogether, this data suggested that Nef residues that are
important for interaction with AP-2 were necessary for Nef
proteins to efficiently antagonize Tetherin.
AP-2 binding sites in Nef are required for Tetherin
downregulation from the cell surface
Since Nef recruits AP-2 to downregulate CD4 from the cell
surface we determined whether Nef could downregulate Tetherin
and whether the AP-2 binding sites were required for this function.
Because we wished to analyze Tetherins from various species, but
only antibodies that recognize the extracellular domain of mouse
(mo) Tetherin that work well in flow cytometric assays are
commercially available, we generated a panel of chimeric
Tetherins. These contained the extracellular domain of mo-
Tetherin linked to the transmembane (TM) and CT domains from
(i) huTetherin, (ii) a modified human Tetherin, termed hu(G-
DIWK), in which 5 amino acids that confer sensitivity to
antagonism by SIVMAC and SIVagm Nef [21] were reintroduced
into the huTetherin CT and (iii) cpzTetherin (Figure S5A).
Notably the structure of moTeherin and huTetherin extracellular
domains are nearly super-imposable [6–8] and clones of 293T cells
stably expressing these Tetherins exhibited the expected pheno-
type in that they inhibited release of HIV-1 virions lacking Vpu
and Nef, but expression of the appropriate Nef protein rescued
particle release (Figure S5B and C).
The various Tetherin-expressing cell lines were transduced with
HIV-1 based vectors expressing Nef-IRES-GFP cassettes and
Tetherin cell surface expression was assessed by FACS using an
antibody that recognizes the extracellular region of moTetherin.
HIV-1 Vpu was used as a control in place of Nef; because it targets
the TM domain of Tetherin which is well conserved between
cpzTetherin and huTetherin, and caused downregulation of all the
chimeric Tetherin proteins used (Figure 4A and 4B). In agreement
with previously published data [18], we observed modest
downregulation of the hu(GDIWK) but not the huTetherin
chimera by SIVMAC Nef (Figure 4A and Figure S6A). Notably,
mutations of either the EXXXLM195 or D204 residues in SIVMAC
Nef abolished this activity. The effects of SIVagmSab Nef on cell
surface hu(GDIWK) Tetherin expression were more pronounced
(Figures 4A and Figure S6A) and again downregulation was
abolished by mutations in either the EXXXLL183 or DD193 motifs
(Figures 4A and Figure S6A). Similarly, SIVcpzGb1 Nef
significantly decreased cell surface expression of the cpzTetherin
chimera and mutation of the DXXXLL165 motif abolished this
ability (Figures 4B and Figure S6B). Importantly, the effects on
Tetherin downregulation were specific, because none of the Nef
proteins affected cell surface expression of the huTetherin chimera
(Figure 4A and 4B and Figure S6A and S6B). Thus the AP-2
binding side in three widely divergent Nef proteins was required
for Tetherin downregulation from the cell surface.
To determine whether Nef affects Tetherin endocytosis, cells
expressing either chimeric hu-moTetherin or cpz-moTetherin
proteins were transduced with vectors expressing no Nef or wild
type SIVcpzGb1 Nef or the SIVcpzGb1 Nef DXXXLL165
(AXXXAA) mutant. Cells were incubated in the cold with a
fluorescently labeled anti-mouse Tetherin antibody, washed, and
then shifted to 37uC. The fraction of Tetherin that was
internalized at various times after the temperature shift was then
determined based on the amount of fluorescence that became
resistant to an acid wash. These data suggested that a fraction
are representative of at least 2 independent experiments. (B) Quantitative Western blot analysis of particle release for HIV-1 based viruses lacking Vpu
and Nef, co-expressed with wild type or mutant SIVagmSab Nef proteins fused to Venus (in trans) in the presence or absence of agmTetherin. Cell and
virion lysates were probed as in (A). The results shown are representative of at least 2 independent experiments. (C) Quantitative Western blot
analysis of particle release for HIV-1 based viruses lacking Vpu and expressing either no Nef, or wild type or mutant SIVcpzGb1 Nef (in cis) in the
presence or absence of cpzTetherin. Cell and virion lysates were probed with an anti-capsid antibody. Cell lysates were also probed with anti-HA
monoclonal antibody and an anti-HIV-1 Nef antibody that also recognizes SIVcpzGb1 Nef. The results shown are representative of at least 2
independent experiments. (D) Y3H analysis of interaction between wild type and mutant SIVagmSab Nef and AP-2 a-s2 hemicomplexes. Yeast cells
were cotransformed with plasmids expressing the various indicated Nef proteins fused to a GAL4 binding domain and the AP-2 s2 subunit and a
plasmid expressing the AP-2 a subunit fused to a VP16 activation domain. Double transformants were selected on dropout plates lacking Leu, Trp
and Met. Pooled colonies from each plate were normalized for cell number and serial dilutions plated on plates lacking Leu, Trp and Met as a control
and plates lacking Leu, Trp, Met and His to detect protein-protein interaction. The results shown are representative of 3 independent experiments.
(See also Figure S3).
doi:10.1371/journal.ppat.1002039.g003
Nef Antagonism of Tetherin Requires AP-2
PLoS Pathogens | www.plospathogens.org 6 May 2011 | Volume 7 | Issue 5 | e1002039(about half) of the Tetherin was rapidly and constitutively
endocytosed within a few minutes, while the remainder was
present at the cell surface for .40 minutes (Figure S7). Wild type
SIVcpzGb1 Nef but not the DXXXLL165 mutant increased the
fraction of cpz-moTetherin that was rapidly internalized within
10 min of the temperature shift to ,100% but did not affect hu-
moTetherin endocytosis (Figure S7). This data suggests that Nef
downregulates Tetherin from the cell surface by increasing the
amount of Tetherin that undergoes rapid endocytosis, to include
the majority of cell surface molecules and that this activity is
dependent on the Nef AP-2 binding site. Alternatively, this data is
also compatible with the hypothesis that a pool of Tetherin is
constitutively rapidly internalized and recycled to the cell surface,
and that Nef interferes with this cycle by causing its entrapment at
intracellular locations.
Nef removes Tetherin from sites of particle assembly
In the presence of huTetherin and absence of HIV-1 Vpu,
fluorescently labeled nascent HIV-1 particles are seen trapped on
the cell surface and colocalizing with huTetherin ([12] and
unpublished data). To determine whether Nef proteins inhibited
colocalization of Tetherin with nascent virions, YFP-labelled HIV-
1 particles were generated in cells stably expressing HA-tagged rh-
or cpzTetherin in the absence or presence of wild-type and mutant
Nef proteins, and surface Tetherin protein revealed by immuno-
staining of non-permeabilized cells. In absence of Nef, nascent
HIV-1 particles exhibited strong co-localization with both
rhTetherin and cpzTetherin (Figure 5A–D). Coexpression of
HIV-1 Nef had no effect on this colocalization, but SIVMAC and
SIVagmSab Nef proteins significantly inhibited the colocalization
between viral particles and rhTetherin (Figure 5A and 5B).
Similar, but more pronounced effects were seen with SIVcpzGb1
Nef, which disrupted the co-localization between HIV-1 particles
and cpzTetherin (Figure 5C and 5D). For both SIVMAC and
SIVcpzGb1 Nef proteins, mutation of the E/DXXXLM/L motif
abolished their ability to remove their respective Tetherin targets
from sites of particle assembly (Figure 5A–D). Thus, Nef proteins
removed Tetherins from sites of particle assembly and this activity
was dependent on motifs critical for Nef-AP-2 interaction.
AP-2 depletion inhibits the ability of Nef to antagonize
Tetherin
To demonstrate that AP-2 is important for Tetherin antagonism
by Nef, we used siRNA based approaches to deplete the a subunit
of AP-2, since Nef binds directly to this subunit [36,37,43].
Transfection of 293T cells with AP-2 a-specific siRNAs reduced
AP-2 a subunit expression levels by ,70–80% (Figure 6A and 6B).
AP-2 a depletion did not affect particle release in the absence of
Tetherin, nor did it affect the ability of Tetherin to inhibit particle
release in the absence of Nef. However, the ability of SIVcpzGb1
Nef to rescue particle release from inhibition by cpzTetherin was
greatly attenuated when AP-2 a was depleted (Figure 6A and
Figure S8A). Similarly, AP-2 a depletion resulted in nearly
complete loss of the ability of SIVMAC Nef to antagonize
rhTetherin (Figure 6B and Figure S8B). Thus, endogenously
expressed AP-2 a is required for Nef proteins to inhibit Tetherin.
Curiously, Tetherin proteins themselves contain a YXXV/M/I
motif in their CT that could mediate binding to AP-2, specifically
Figure 4. Mutation of Nef residues involved in AP-2 binding affects cell surface downregulation of Tetherin. (A) Surface staining of
cells stably expressing chimeric mo-Tetherin containing the hu-Tetherin CT unmodified or with a 5 amino acid (GDIWK) insertion. Cells were
transduced with HIV-based vectors expressing the indicated Nef proteins or HIV-1 Vpu and IRES-GFP and stained with anti-mouse Tetherin antibody
conjugated to APC. The median fluorescence in the APC channel of GFP positive cells is plotted as a proportion of the median fluorescence of cells
transduced with a control empty vector which was set at 100%. Data is plotted as the mean and standard deviation of 3 independent experiments.
(B) Surface staining of cells stably expressing chimeric mo-Tetherin containing the hu- or cpz-Tetherin CT. Cells were transduced stained and
fluorescence quantitated as in (A). (See Figures S5 and S6).
doi:10.1371/journal.ppat.1002039.g004
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PLoS Pathogens | www.plospathogens.org 7 May 2011 | Volume 7 | Issue 5 | e1002039Figure 5. AP-2 binding sites in Nef are required to remove Tetherin from sites of particle assembly. (A) Immunofluorescence analysis of
cells stably expressing HA-tagged rhTetherin and transfected with HIV-1 proviral plasmids expressing YFP-labelled Gag and various Nef proteins (for
details see Materials and Methods). Tetherin appears red and viral particles appear green. Representative images of the apical portion of a cell are
shown for each Nef protein. (B) Quantitative analysis of co-localization between rhTetherin and YFP-labeled HIV-1 particles in the presence of the
indicated Nef proteins. Each symbol represents the value of the Pearson’s coefficient for an individual cell and the horizontal line represents the mean
value for 15 to 30 cells. (C) As in (A) but cells expressed HA-tagged cpzTetherin. (D) Quantitative analysis of co-localization between cpzTetherin and
YFP-labeled viral particles, as in (B).
doi:10.1371/journal.ppat.1002039.g005
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to m2 and to be subject to AP-2 mediated endocytosis [45].
huTetherin has also been reported to undergo AP-2-dependent
endocytosis, and two tyrosine residues (Y6 and Y8) in the
huTetherin CT were found to be important for AP-2 a subunit
binding [46]. To determine whether these residues were important
for Tetherin activity, or for sensitivity to Nef, we mutated both
tyrosines in cpz- and rh-Tetherin. Increasing amounts of
unmodified or mutant cpzTetherin were co-expressed with a
Vpu-defective HIV-1 virus that expressed either no Nef or
SIVcpzGb1 Nef. In the absence of Nef, viral particle release was
inhibited to similar extents by both the mutant and the unmodified
Tetherin proteins (Figure 7C). Similar results were obtained when
increasing amounts of unmodified or mutant rhTetherin were co-
expressed with SIVMAC or SIVMACDNef (Figure 7D). Importantly,
for both cpzTetherin/SIVcpzGb1 Nef and rhTetherin/SIVMAC
Nef, the presence or absence of the reported AP-2 binding site in
the Tetherin CT did not affect sensitivity to antagonism by the
corresponding Nef protein (Figure 7C and 7D). Furthermore,
cpzTetherin downregulation by SIVcpzGb1 Nef was also
unaffected by mutation of the cpzTetherin AP-2 binding site
(Figure S9). Thus, interactions between tyrosine motif in the
Tetherin CT and AP-2 are not required for Tetherin activity, or
sensitivity to Nef proteins. Rather, interactions between Nef and
AP-2 are key for its Tetherin antagonist function.
Discussion
Here, we show that Nef antagonizes Tetherin by decreasing its
levels at the cell surface and particularly at sites of particle
assembly. We also show that the ability of Nef to antagonize
Tetherin is lost when residues that are important for AP-2 binding
are mutated, or when AP-2 a expression is reduced using RNA
interference. These results strongly suggest that the interaction of
Nef with AP-2 is required for the removal of Tetherin from sites of
virion assembly and antagonism of its antiviral function.
Additionally, we identified three amino acids at the C-terminal
loop of SIVcpzGb1 Nef, that are key determinants of its ability to
antagonize Tetherin. However, our data suggest that other
residues within the C-terminal loop and particularly within amino
acids 148 to 167 also contribute to Tetherin antagonism.
Together, these findings suggest a model in which Nef interacts
with Tetherin and simultaneously with AP-2 via the Nef C-
terminal loop and that the formation of this complex impairs the
ability of Tetherin to be incorporated into virions, because it
becomes sequestered by Nef and AP-2 away from sites of particle
release, and either internalized or trapped at intracellular locations
more efficiently than it would otherwise be. Interestingly, the
decreased levels of Tetherin at the cell surface in the presence of
Nef do not lead to an obvious reduction in the total Tetherin
protein levels in the cell (Figure 3 and Figure 4 and data not
shown). This data suggests that in contrast to CD4 [32], Tetherin
internalization or intracellular retention by Nef-AP-2 does not lead
to Tetherin degradation.
The reciprocal specificity associated with the sequence require-
ments in both Nef and Tetherin for antagonism are most
consistent with the notion that the two proteins directly interact
with each other. Unfortunately, we were not able to demonstrate a
specific physical interaction between Nef and Tetherin using in
vitro binding assays with recombinant proteins, yeast two-hybrid
Figure 6. AP-2 is required for Nef to antagonize Tetherin. (A) Quantitative Western blot analysis of particle release from cells transfected with
the indicated siRNA, an HIV-1 provirus lacking Vpu (and expressing no Nef or SIVcpzGb1 Nef) and cpzTetherin or a control plasmid. Cell and virion
lysates were probed with an anti-capsid antibody. Cell lysates were also probed with anti-Nef, anti-HA and anti-AP-2a antibodies. Numbers above the
AP-2 a blot represent measurement of AP-2 a protein expression levels (LICOR). A representative of 2 independent experiments is shown. (B) Same as
(A) but particle release by SIVMAC or SIVMACDNef in the presence or absence of rhTetherin is shown. A representative of 2 independent experiments is
shown.
doi:10.1371/journal.ppat.1002039.g006
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cells. This suggests that the putative Nef-Tetherin interaction (if it
occurs) is of low affinity or unstable outside the confines of a cell
membrane. Interestingly, the Nef C-terminal flexible loop, in
which key determinants of Tetherin antagonism reside, also
mediates interaction with the AP-2 complex. In fact, two key
amino acids identified in SIVcpzGb1 Nef as important for
Tetherin antagonism (T162 and C163) are embedded within the
D/EXXXLL motif that is critical for interaction with the AP-2 a
subunit (specifically within the sequence DNNCLL). Mutations at
these variable positions in the otherwise very well conserved D/
EXXXLL motif do not grossly affect the ability of Nef to
downregulate CD4 (Figure S1), indicating that AP-2 binding and
Tetherin antagonism are separable activities. Nonetheless, the AP-
2 binding site and residues required for Tetherin antagonism are
in close physical proximity. It is also noteworthy that the
cytoplasmic tails of primate Tetherins contain a classical sorting
signal recognized by the AP-2 m subunit [44]. Indeed, rat Tetherin
has been shown to interact with the AP-2 m subunit [45] but
huTetherin endocytosis has been reported to be dependent on the
AP-2 a subunit and to be dependent on two tyrosine residues, one
of which is part of the YXXV motif [46]. Importantly, however,
although Tetherin may interact directly with AP-2, our findings
indicate that this interaction is not required for virus restriction nor
for sensitivity to Nef. This is in contrast with a recent report that
demonstrates that the tyrosine residues in rhTetherin are critical
for antagonism by an adapted SIVmac239 Env protein that causes
rhTetherin downregulation, although the role of AP-2 in this
activity was not determined [47].
Given the close proximity of amino acids putatively involved in
Tetherin recognition to the AP-2 binding site, it might appear
difficult to envisage how Nef might simultaneously bind to
Figure 7. Direct binding of Tetherin to AP-2 is dispensable for Tetherin function and antagonism. (A) Quantitative Western blot analysis
of particle release from cells expressing an HIV-1 provirus lacking Vpu and expressing no Nef or SIVcpzGb1 Nef in the absence or presence of
increasing amounts of unmodified or Y6A/Y8A mutant cpzTetherin. Cell and virion lysates were probed with anti-capsid and anti-HA antibodies.
Numbers at the bottom indicate measurement of viral particle release (LICOR). A representative of 2 independent experiments is shown. (B)
Quantitative Western blot analysis of particle release from cells expressing SIVMAC239 or SIVMAC239DNef in the absence or presence of increasing
amounts of wild type or Y6A/Y8A mutant rhTetherin. Cell and virion lysates were probed as in (A). A representative of 2 independent experiments is
shown. (See Figure S9.).
doi:10.1371/journal.ppat.1002039.g007
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interspersed with those comprising the AP-2 binding site (within
the D/EXXXLL motif) in Nef likely form only part of the
determinant for Tetherin recognition. Indeed, mutation of the
two residues alone within the D/EXXXLL motif that are
important for Tetherin antagonism, is not sufficient to abolish the
Tetherin antagonizing activity of SIVcpzGb1 Nef. Additionally,
introduction of the three residues Q152/N162/C163 (that
include N162/C163 within the DXXXLL motif) identified as
critical for Tetherin antagonism in SIVcpzGb1 Nef to HIV-1 Nef
was not sufficient to confer anti-Tetherin activity at the levels
obtained with wild type SIVcpzGb1 Nef. Interestingly, residues
N162/C163 are naturally found in a number of HIV-1 Nef
proteins, including in Nef from strains JR-CSF and YU-10x that
have been previously shown to have no activity against
cpzTetherin [20]. Therefore, the context within which Nef
residues are mutated determines whether they confer anti-
Tetherin activity and several different residues within the C-
terminal flexible loop of Nef contribute to Tetherin antagonism.
It is possible that Nef forms multiple (perhaps individually weak)
contacts with Tetherin, only one of which is mediated by an
overlapping motif with the Nef-AP-2 binding site. One possible
model, that is consistent with our findings, is that binding of the
flexible C-terminal loop of Nef to AP-2 results in the formation of
the site on Nef that binds to Tetherin. It is even possible that both
AP-2 and Nef residues contribute to the formation of the
Tetherin binding site. Alternatively, it has been reported that Nef
can form dimers [41], so it is possible that one molecule in a Nef
dimer interacts with Tetherin and the other with AP-2. However,
arguing against this notion is our finding that mutation of a
residue predicted to be required for SIVMAC Nef dimerization did
not affect its ability to counteract rhTetherin (Figure 3A). Finally,
we cannot exclude the possibility that other cellular proteins,
including other AP complexes, act as a bridge between the Nef-
AP-2 complex and Tetherin, although this possibility seems
unlikely due to the sequence specificity associated with the Nef-
Tetherin antagonism.
Of the known accessory proteins encoded by lentiviruses, none
has been ascribed more functions than Nef (reviewed in [28]). Nef
is critical for efficient replication in vivo [48–50] and at least some
of its reported functions, e.g. CD4 and MHC-I downregulation,
are likely to play a significant role in pathogenesis. While it
remains to be proven that Tetherin antagonism is required for
efficient replication and dissemination of enveloped viruses in vivo,
the finding that primate lentiviruses have evolved diverse strategies
to counteract this antiviral protein suggests that it is. The
identification of Nef domains and sequences that are required
for Tetherin antagonism but not for other Nef activities could
potentially allow the design of experiments to determine the
importance of this function in viral pathogenesis in vivo.
We note that Nef antagonizes Tetherin via a mechanism that is
related to that which it employs to downregulate CD4, namely
recruitment of the AP-2 complex. Thus, it appears that Nef can
parasitize the AP-2 complex for multiple ends. In a sense, the
acquisition of Tetherin antagonism activity appears to be the result
of the modification of an existing activity, namely CD4
downregulation, by broadening the array of target proteins to
which AP-2 is recruited to include Tetherin. A similar concept
might apply in the evolution of Vpu function, where (again) CD4
downregulation and Tetherin antagonism may proceed by similar
mechanisms, with the viral accessory protein acting to recruit
cellular factors (in that case b-TRCP [51–53]) to remove two
different cellular molecules. Thus, lentiviruses can exploit Nef, and
perhaps other accessory gene products, as somewhat plastic
adaptors to recruit a given protein complex, in this case AP-2, to
diverse targets so as to manipulate host cells to provide a more
permissive environment for virus replication and dissemination.
Materials and Methods
Plasmid construction
Plasmids expressing wild-type HIV-1 and SIVcpz Gb1 Nef
proteins have been previously described [20]. Chimeric proteins
were made by overlap-extension PCR using external primers
introducing XbaI and MluI sites at the 59end and 39end of the Nef
coding sequence, respectively and internal primers. PCR products
were cloned into pCG-IRESGFP [21]. The HIV-1-based proviral
plasmids, pBRHIV-1NL4-3DVpu, lacking Vpu and expressing
wild-type versions of Nef proteins from HIV-1, SIVcpz Gab,
SIVMAC239, or SIVagmSab Nef in cis, have been previously
described [20]. Mutations in the Nef coding sequences of these
plasmids were generated using overlap-extension PCR and
BamHI (in the Env coding region) and MluI (at the 39-end of
the Nef coding region) sites in pBRHIV-1NL4-3DVpu plasmid.
The same strategy was used to introduce wild type and mutant Nef
proteins into a pBRHIV-1NL4-3DVpuDNef plamids bearing YFP
embedded in sequences encoding the stalk region of matrix (MA).
The pV1-derived plasmids encoding full length SIVMAC23 or
SIVMAC239DNef proviruses have been previously described [21].
pCR3.1 plasmids were used to express wild-type and mutant
SIVMAC239 and SIVagmSab Nef proteins fused to Venus at their
C-terminus in trans. To express Nef proteins in 293T cell lines
stably expressing Tetherin, Nef-IRES-GFP containing regions
from pCG derivatives were transferred using SnaBI-NotI
fragments (encompassing the CMV promoter-Nef-IRES-GFP
cassette) into pCCGW, a HIV-based retroviral vector derived
from pHRSIN-CSGW [54] by replacing the SSFV promoter with
that from CMV. Plasmids expressing HA-tagged Tetherin proteins
were constructed as previously described [12,55]. Mutations of the
tyrosine residues in the CT of rh- and cpzTetherin were
introduced by overlap-extension PCR. Chimeric hu-mo or hu-
GDIWK-mo or cpz-mo Tetherin proteins, were generated by
overlap-extension PCR, using hu, hu-GDIWK [21] or
cpzTetherin as template for the CT and TM domains and
moTetherin as template for the extracellular domain. PCR
products were inserted into a retroviral vector pLHCX (Clontech).
All cloned coding sequences were verified by DNA sequencing.
Oligonucleotide sequences are available upon request.
Transfections and FACS analysis
293T and TZMbl cells were maintained under standard
conditions. Transfection protocols have been previously described
[21]. Several 293T-derived cell lines stably expressing HA-tagged
rh- or cpzTetherin and chimeric hu-mo, hu-GDIWK-mo and cpz-
mo Tetherin were derived by transduction of 293T cells with the
corresponding retroviral plasmids, followed by selection in
hygromycin (5 mg/ml).
To determine the ability of Nef proteins to counteract Tetherin,
cells were transfected with 100-200 ng of pCG-IRES-GFP derived
plasmids expressing various Nef proteins, 400–500 ng pBRHIV-
1NL4-3DVpuDNef or SIVMACDNef and 20–25 ng of pCR3.1
Tetherin-HA expression plasmids or empty expression vector.
To test the activity of tyrosine mutant rh- and cpzTetherin
proteins, transfections were performed as above but with
increasing amounts (0 ng, 5 ng, 10 ng, 20 ng, 40 ng, 80 ng/well)
of each Tetherin-HA expression plasmid. The total amount of
DNA was held constant by supplementing the transfection with
empty expression vector.
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generated by transfecting 5mg of pCCGW plasmids expressing
various Nef proteins or HIV-1 Vpu, 5mg of an HIV-1 Gag-Pol
expression plasmid and 1mg of VSV-G expression plasmid in 293T
cells (10 cm dishes) and used to inoculate cells stably expressing
chimeric moTetherin proteins. At 48 h post-infection, cells were
detached from plates with 5 mM EDTA in PBS and stained for
cell surface Tetherin expression with anti-moTetherin antibody
conjugated to APC (anti-mPDCA-1-APC, Miltenyi Biotec). The
amount of cell-associated APC and GFP fluorescence was
measured with an LSRII flow cytometer (BD).
Virus release and immunoblot assays
Experiments were performed as previously described [21].
Immunoblots were probed with the following antibodies: rabbit
anti-HA antibody (Rockland) or mouse anti-AP2 a (a-Adaptin 1/
2, Santa Cruz Biotech.), mouse anti-HIV-1-p24CA (183-H12-5C),
mouse anti-HIV-1-Nef (1539) or mouse anti-SIVMAC-Nef (17.2)
(2659) (from the NIH AIDS Research and Reagents Program),
followed by anti-rabbit or anti-mouse antibodies conjugated to
IRDye680 or IRDye800 CW and scanned with an Odyssey
Infrared Imager (LICOR).
Microscopy
Cells stably expressing HA-tagged cpzTetherin or rhTetherin
were seeded on 3.5-cm, glass-bottomed dishes coated with poly-L-
Lysine (Mattek). Cells were transfected with 150 ng of an HIV-1
proviral plasmid (pBRHIV-1NL4-3DVpuDNef) that was engi-
neered to express various Nef proteins and 150 ng of an identical
construct that expressed YFP embedded within the MA domain of
Gag (pBRHIV-1NL4-3DVpuDNef-MA(YFP)) using PEI (Poly-
Sciences). At 48 h post-transfection, cells were fixed with 4%
paraformaldehyde and incubated with mouse anti-HA.11 mono-
clonal antibody (Covance) followed by anti-mouse IgG Alexafluor-
594 conjugate (Molecular Probes). A Z-series of images was
captured from the top apical half of the cells using an Olympus
IX70-based Deltavision microscope and were then deconvolved
with SoftWorx software (Applied Precision). For each cell,
colocalization of Tetherin with virions was measured by tracing
regions of interest in each Z-slice so as to analyze only the cell
surface, and the Pearson’s correlation coefficient for colocalization
for each individual cell was calculated using SoftWorx software.
For the Nef-AP-2 co-localization assays, 293T cells, seeded on
3.5-cm glass-bottomed dishes coated with poly-L-Lysine (Mattek),
were transfected with 100 ng of plasmids expressing Nef proteins
fused to Venus at their C-terminus. At 48 h post-transfection, cells
were fixed with 4% paraformaldehyde, permeabilized with 0.1%
Triton and incubated with mouse anti-AP-2 a momoclonal
antibody (Santa Cruz Biotech. a-Adaptin 1/2) followed by anti-
mouse IgG Alexa Fluor-594 conjugate (Molecular Probes). A Z-
series of images was acquired using Deltavision microscope, and
colocalization between Nef and AP-2 was inspected using images
of the cell surface acquired at the cell coverslip interface.
Tetherin internalization assays
The internalization of tetherin from cell surface was determined
by flow cytometry assay as described previously for other cell
surface markers [56,57]. Briefly, cells stably expressing chimeric
moTetherin proteins were transduced with pCCGW Nef-IRES-
GFP vectors plasmids. At 40 h post-infection, 10
7 cells were
incubated with saturating amounts of anti-moTetherin antibody
conjugated to APC (anti-mPDCA-1-APC, Miltenyi Biotec) in
DMEM containing 0.5% bovine serum albumin on ice for 30 min.
Following removal of excess unbound antibody, aliquots of 10
6
cells were shifted to 37uC for various periods of time. Then, each
sample was split into two aliquots, which were diluted with
DMEM under neutral (pH 7.4) or acid (pH 2) conditions and
incubated for 1 min on ice. Samples were then washed and
fluorescence measured with an LSRII flow cytometer (BD).
Yeast-3-hybrid assays
SIVagmSab Nef proteins were fused to the GAL4 DNA-binding
domain in the pBridge vector (Clontech) also expressing the s2
subunit of AP-2 (a kind gift of Juan Bonifacino). The a subunit of
rat AP-2 was cloned into pVP16/HA [58]. The protocol used
subsequently has been previously described [36,37] except that
Saccharomyces cerevisiae strain Y190 was used and transformed using
the Gietz lab kit (Molecular Research Reagents Inc.).
Supporting Information
Figure S1 Mapping Tetherin antagonism determinants in Nef.
(A and C) Quantitative fluorescence-based Western blot analysis of
particle release. HIV-1 lacking Vpu and Nef was expressed
together with the indicated Nef proteins (in trans) in the presence or
absence of cpzTetherin. Virion lysates were probed with an anti-
capsid antibody and p24 quantitation in virion samples was
measured using LICOR. Average and standard deviation of 2-3
independent experiments is shown. (B and D) Cell lysates were
probed with an anti-HIV-1 Nef antibody that also recognizes
SIVcpzGb1 Nef. (E) Nef-mediated CD4 downregulation. TZMbl
cells transfected (using Lipofectamine2000) with 1mg of pCG-
IRES-GFP plasmids expressing various Nef proteins depicted in
Figure 1. Cells were stained 48hrs post-transfection with a mouse
anti-human CD4 antibody conjugated to Alexa700 (BD Pharmi-
gen). Cell associated fluorescence in the 700nm and GFP channels
were measured using an LSRII flow cytometer (BD). The median
fluorescence intensity in the 700nm channel of GFP-positive cells
is plotted. Average and standard deviation of 2-3 independent
experiments is shown.
(TIF)
Figure S2 Identification of Nef amino acids important for
Tetherin antagonism. (A) Quantitative fluorescence-based West-
ern blot analysis of particle release. HIV-1 lacking Vpu and Nef
was expressed together with the Nef indicated proteins (in trans)i n
the presence or absence of cpzTetherin. Virion lysates were
probed with an anti-capsid antibody and p24 quantitation in
virion samples was measured using LICOR. Average and standard
deviation of 3 independent experiments is shown. (B) Cell lysates
were probed with an anti-HIV-1 Nef antibody that also recognizes
SIVcpzGb1 Nef. (C) TZMbl cells transfected (using Lipofecta-
mine2000) with 1mg of pCG-IRES-GFP plasmids expressing
various Nef proteins depicted in Figure 1. Cells were stained 48hrs
post-transfection with a mouse anti-human CD4 antibody
conjugated to Alexa700 (BD Pharmigen). Cell associated fluores-
cence in the 700nm and GFP channels were measured using an
LSRII flow cytometer (BD). The median fluorescence intensity in
the 700nm channel of GFP-positive cells is plotted. Average and
standard deviation of 2-3 independent experiments is shown.
(TIF)
Figure S3 Mutation of Nef residues required for AP-2 binding
abolishes Tetherin antagonism. (A) Quantitative Western blot
analysis of particle release for SIVMAC based viruses lacking Nef,
co-expressed with the indicated wild type or mutant SIVMAC Nef
proteins fused to Venus (in trans) in the presence or absence of
rhTetherin. Virion lysates were probed with an anti-HIV-1-capsid
antibody and p24 in virion samples was quantitated using LICOR.
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shown. (B) Quantitative Western blot analysis of particle release
for HIV-1 based viruses lacking Vpu and Nef, co-expressed with
wild type or mutant SIVagmSab Nef proteins fused to Venus (in
trans) in the presence or absence of agmTetherin. Virion lysates
were probed with an anti-HIV-1-capsid antibody and p24 in
virion samples was quantitated using LICOR. Average and
standard deviation of 2-3 independent experiments is shown. (C)
Quantitative Western blot analysis of particle release for HIV-1
based viruses lacking Vpu and expressing no Nef or wild type or
mutant SIVcpzGb1 Nef (in cis) in the presence or absence of
cpzTetherin. Virion lysates were probed with an anti-HIV-1-
capsid antibody and p24 in virion samples was quantitated using
LICOR. Average and standard deviation of 2-3 independent
experiments is shown.
(TIF)
Figure S4 Nef-AP-2 co-localization in mammalian cells. Immu-
nofluorescence analysis of cells transfected with the indicated Nef-
Venus fusion (shown in green) protein (for details see Materials
and Methods). Endogenous AP-2 was detected using an antibody
against the AP-2 a subunit followed by an Alexa594 secondary
(shown in red). Representative images of the cell in contact with
the coverslip for each Nef are shown.
(TIF)
Figure S5 Inhibition of particle release in cell lines stably
expressing moTetherin chimeras. (A) Schematic representation of
the chimeric Tetherin proteins used in this study. The drawing
outlines the structural organization of Tetherin in the lipid bilayer
(black lines with gray filling) with the top being the extracellular
medium and the bottom the intracellular milieu. Purple shapes
represent moTetherin-derived regions, black lines represent
huTetherin-derived regions and teal lines represent cpzTetherin-
derived regions. (B) Quantitative Western blot analysis of virion
release from cells stably expressing chimeric moTetherin contain-
ing the hu-Tetherin CT or the hu-Tetherin CT with a 5 amino
acid (GDIWK) insertion. Cells were infected with VSV-G
pseudotyped HIV-1 based viruses (pBRHIV-1NL4-3DVpu) lack-
ing Vpu and encoding the indicated Nef proteins. Cell and virion
lysates were probed with an anti-capsid antibody. Numbers below
each lane represent the measurement of p24 CA associated with
released virus particles (LICOR). (C) Quantitative Western blot
analysis of virion release from cells stably expressing chimeric
moTetherin containing the hu- or cpz-Tetherin CT. Experiments
were performed as described in (B).
(TIF)
Figure S6 Tetherin cell surface downregulation by Nef.
Representative experiments used to generate the graphs in
Figure 4. (A) Surface staining of cells stably expressing chimeric
moTetherin containing the huTetherin CT that was either
unmodified or included a 5 amino acid (GDIWK) insertion. Cells
were infected with VSV-G pseudotyped HIV-1-based viral vector
stocks (pCCGW) expressing the indicated Vpu or Nef protein
linked to an IRES-GFP cassette. Control viruses were generated
using pCCGW that did not express Vpu or Nef. At 48h post-
infection, cells were stained for Tetherin expression with anti-
mouse Tetherin antibody conjugated to APC. Cell associated
fluorescence in the APC and GFP channels was measured using an
LSRII flow cytometer (BD). (B) Surface staining of cells stably
expressing chimeric moTetherin containing the hu- or cpz-
Tetherin CT. Cells were infected and stained as in (A).
(TIF)
Figure S7 Nef enhances the rate of Tetherin internalization.
Cells stably expressing hu- or cpz-moTetherin chimeras were
transduced with vectors expressing no Nef or SIVcpzGb1 Nef wild
type or DXXXLL/AXXXLL mutant. Cells were then stained
with anti-moTetherin antibody at 4uC and shifted to 37uC. At the
indicated times thereafter cells were washed at acid pH, that
should remove all surface-bound antibody. The data is plotted as
the proportion of the fluorescent intensity observed at each time
point relative to the neutral pH washed, T=0 sample.
(TIF)
Figure S8 AP-2 is required for Nef to antagonize Tetherin. (A)
Quantitative Western blot analysis of virion release from cells
transfected with the indicated siRNA, an HIV-1 provirus lacking
Vpu (and expressing no Nef or SIVcpzGb1 Nef) and cpzTetherin
or a control plasmid. Virion lysates were probed with an anti-
capsid antibody and p24 was quantitated in virion samples
(LICOR). Average and standard deviation of 2 independent
experiments is shown. (B) Same as (A) but particle release by
SIVMAC or SIVMACDNef transfected cells in the presence or
absence of rhTetherin is shown.
(TIF)
Figure S9 Cell surface downregulation of mutant cpzY6A/Y8A-
Tetherin by SIVcpzGb1 Nef. Cells stably expressing moTetherin
containing the cpzTetherin CT and TM domains with mutations
at residues Y6A and Y8A were transduced with HIV-based viral
vectors (pCCGW) expressing Nef-IRES-GFP. Cell surface
Tetherin staining was performed using an anti-mouse Tetherin
antibody conjugated to APC. Median fluorescence in the APC
channel of GFP positive cells is plotted relative to the median
fluorescence of cells infected with a control empty vector (that does
not express Vpu or Nef) which was set as 100%. Data is plotted as
the mean and standard deviation of 2 independent experiments.
Results obtained with cells stably expressing moTetherin contain-
ing the hu- or cpz-Tetherin CT are plotted for comparison.
(TIF)
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